Factors Influencing Physician Treatment Strategies in Crotaline Snake Envenomation by Ramirez-Cueva, Fatima et al.
OBJECTIVE
This study sought to determine 
associations between physician 
treatment strategies, snake 
identification (ID), venom effects, bite 
location and patient presentation.
Crotaline snake envenomation is a 
potentially serious medical condition 
that affects thousands of Americans 
each year. (1,2) There continues to be 
variation in treatment practices by 
physicians in the United States despite 
guidelines establishing the use of 
antivenom and supportive care as the 




A cross-sectional review of electronic 
medical records (EMR) for patients 
diagnosed with venomous snake bites 
from July 1, 2014 to August 31, 2019 
was completed. Data collected from 
the EMR included: patient 
demographics, transfer information, 
length of hospital and ICU stays, snake 
ID, bite site, progression of local tissue 
effects, additional clinical and lab 
results, patient comorbidities and 
complications, and provider 
treatment strategy.
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RESULTS & CONCLUSION
Envenomated patients are likely to be treated with antivenom if there was progression of local tissue effects. For patients in this study who were bitten by 
copperheads and unknown snakes, close observation without antivenom administration had favorable outcomes including shorter hospital stays and likely 
decreased hospital costs.
2 None of the 15 patients who were under 
observation (no antivenom) for treatment went 
to the ICU. These patients experienced the 



































77.9% of patients who received antivenom also 
received an opioid for pain management vs. 
33.3% of patients under observation (no 































In a regression model of treatment strategy, 
progression of local tissue effects was a 
statistically significant predictor of receiving 
antivenom (Table 2).
4
Table 2. Standardized Coefficients from an 






















Notes: N=81. Adj R2=0.225. Numbers in 
parentheses are standard errors. ***p<0.001
Of the 83 patients who met inclusion criteria, 68 
patients (81.9%) received antivenom (Table 1).
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Hospital stays were longest for patients 
envenomated by an identified rattlesnake or 
cottonmouth (“Non-Copperhead”) compared to 


































Rattlesnake and cottonmouth envenomations
(“Non-Copperhead”) used more vials of 





























a, b a b
*a, b Statistically significant groups, Dunn’s post-hoc comparisons tests (p<0.05)
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